PEG화 단백질 시장 보고서 : 제품별, 단백질 유형별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global PEGylated proteins market size reached USD 1.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.0 Billion by 2033, exhibiting a growth rate (CAGR) of 8.43% during 2025-2033. The global market is primarily driven by their enhanced therapeutic efficacy, advancements in PEGylation technologies, and the rising global prevalence of chronic diseases, fueling robust investments in biopharmaceuticals that offer improved treatment outcomes and sustained drug performance.

PEGylated proteins are biomolecules that have been modified by covalent conjugation with polyethylene glycol (PEG). It involves the PEGylation technique that improves the pharmacokinetic behavior of the medicine by altering the biological molecule's physical and chemical characteristics, such as its conformation, electrostatic binding, and hydrophobicity. PEGylated proteins are widely used in therapeutic applications, such as vaccines, hormone replacement therapy, genetic disorders, anemia, and blood clotting disorder. It is also used in various drugs for diseases, including kidney disease, multiple sclerosis, hemophilia, and cancers. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic.

PEGylated Proteins Market Trends:

The rising prevalence of chronic diseases, such as kidney ailments, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis across the globe is one of the key factors driving the market growth. PEGylated proteins are widely used to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and prevent the progression of chronic kidney disease. In line with this, the widespread product utilization in cancer treatment to deliver chemotherapy drugs directly to cancer cells and reduce the side effects on healthy cells is favoring the market growth. Apart from this, various improvements in the PEGylation technology, such as the development of new PEGylation methods that can produce smaller and more complex molecules, are providing an impetus to the market growth. Additionally, the widespread adoption of PEGylation to improve the stability and half-life of colony-stimulating factors (CSFs), making them more effective as therapeutic agents, is acting as another growth-inducing factor. Furthermore, the rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving its efficiency, is propelling the market growth. Other factors, including the increasing number of product approvals for PEGylated proteins, development in the field of biotechnology and molecular biology engineering, the integration of PEG molecules in biopharmaceuticals and the associated advantages, rising geriatric population, and the implementation of various government initiatives to increase regulatory standards in the pharmaceutical industry, are anticipated drive the market further toward growth.

Key Market Segmentation:

Product Insights:

• Consumables
• PEGylation Reagents
• PEGylation Kits
• Services
• A detailed breakup and analysis of the PEGylated proteins market based on the product has also been provided in the report. This includes consumables (PEgylation reagents and PEgylation kits) and services. According to the report, consumables accounted for the largest market share.

Protein Type Insights:

• Colony Stimulating Factors
• Interferons
• Erythropoietin
• mAbs
• Recombinant Factor VII
• Others

Application Insights:

• Cancer Treatment
• Hepatitis
• Chronic Kidney Diseases
• Hemophilia
• Multiple Sclerosis
• Gastrointestinal Disorders
• Others

End User Insights:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes

Regional Insights:

• North America
• United States
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for PEGylated proteins. Some of the factors driving the North America PEGylated proteins market included the rising geriatric population, increasing prevalence of chronic diseases, and extensive research and development (R&D).

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global PEGylated proteins market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Biomatrik Inc., Creative PEGWorks, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio Inc., NOF America Corporation (NOF Corporation), Profacgen, Thermo Fisher Scientific Inc., etc.

Key Questions Answered in This Report

• 1. How big is the global PEGylated proteins market?
• 2. What is the expected growth rate of the global PEGylated proteins market during 2025-2033?
• 3. What are the key factors driving the global PEGylated proteins market?
• 4. What has been the impact of COVID-19 on the global PEGylated proteins market?
• 5. What is the breakup of the global PEGylated proteins market based on the product?
• 6. What is the breakup of the global PEGylated proteins market based on the protein type?
• 7. What is the breakup of the global PEGylated proteins market based on the application?
• 8. What is the breakup of the global PEGylated proteins market based on the end user?
• 9. What are the key regions in the global PEGylated proteins market?
• 10. Who are the key players/companies in the global PEGylated proteins market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global PEGylated Proteins Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 PEGylation Reagents
    • 6.1.2.2 PEGylation Kits
  • 6.1.3 Market Forecast
• 6.2 Services
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Protein Type

• 7.1 Colony Stimulating Factors
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Interferons
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Erythropoietin
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 mAbs
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Recombinant Factor VII
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Cancer Treatment
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Hepatitis
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Chronic Kidney Diseases
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Hemophilia
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Multiple Sclerosis
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Gastrointestinal Disorders
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Contract Research Organizations
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Academic and Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abcam plc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Biomatrik Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Creative PEGWorks
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Iris Biotech GmbH
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 JenKem Technology USA Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Laysan Bio Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 NOF America Corporation (NOF Corporation)
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Profacgen
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Thermo Fisher Scientific Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report